Vanguard Group Inc Metacrine, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.43 - $0.55 $83,391 - $106,663	-193,934 Reduced 43.25%	254,492 $123,000
Q2 2022 Aug 12, 2022	BUY	$0.36 - $0.63 $5,443 - $9,526	15,122 Added 3.49%	448,426 $225,000
Q1 2022 May 13, 2022	BUY	$0.43 - $0.7 $396 - $645	922 Added 0.21%	433,304 $264,000
Q4 2021 Feb 14, 2022	BUY	$0.64 - $3.83 $12,800 - $76,600	20,000 Added 4.85%	432,382 $291,000
Q3 2021 Nov 12, 2021	BUY	$2.61 - $3.84 $11,228 - $16,519	4,302 Added 1.05%	412,382 $1.42 Million
Q2 2021 Aug 13, 2021	BUY	$3.37 - $5.73 $1.38 Million - $2.34 Million	408,080 New	408,080 $1.55 Million

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.